Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Thousands of tonnes of colistin ‘shipped to farms’ in 10 countries
Timothy Walsh, a global expert on antibiotic resistance, said the use of colistin in poultry farming is “complete and utter madness”.
Study finds countries are using the antibiotic as a growth promoter

Nearly 3,000 tonnes of the ‘last resort’ antibiotic colistin was shipped to countries in Asia and Central America last year, for use on farms. This is according to a study by the Bureau of Investigative Journalism.

Colistin is a critically important human medicine, used to treat infections which have become resistant to nearly all other drugs. The World Health Organisation (WHO) has called for its use to be restricted in animals and banned as a growth promoter.

However, the bureau says the drug is being used on Indian farms to make animals gain weight faster, to prevent disease, and as a replacement for good biosecurity. At least five animal pharmaceutical companies in the country are said to be openly advertising products containing colistin as growth promoters.

The bureau tracked more than 2,800 tonnes of veterinary colistin that was sent to India, Vietnam, South Korea, Russia, Nepal, Guatemala, Colombia, Bolivia, Mexico and El Salvador in 2016. It is thought the true total is likely to be higher as products may be shipped under the brand name rather than being labelled colistin - and to other countries where customs data is not public.

Professor Ramanan Laxminarayan, director of the Centre for Disease Dynamics, Economics and Policy in Delhi, said farmers in India use antimicrobials - which are cheap - as a substitute for good farming practices. He believes change will be driven by consumer pressure rather than regulation.

Timothy Walsh, a global expert on antibiotic resistance, called the findings “deeply worrying” and said the use of colistin in poultry farming is “complete and utter madness”. He warned that colistin will be a “dead” drug by 2030 unless action is taken, resulting in serious, untreatable infections.

By contrast, the UK uses less than a tonne of colistin a year in agriculture. Using antibiotics as growth promoters has been banned in the EU since 2006 and was made illegal in the US last year.

Professor Walsh, of Cardiff University, was part of the team who found the colistin-resistant gene mcr-1 in Chinese pigs in 2015. The discovery prompted worldwide panic in the medical community as mcr-1 allows infections to develop colistin resistance, leading to untreatable infections.

The gene has now been detected in bacteria from animals and humans in over 30 countries across four continents. Another four colistin-resistant genes (mcr-2 to mcr-5) have since been discovered.

Professor Walsh added: “Colistin-resistant bacteria will spread on the chicken farms, in the air surrounding them, contaminate the meat, spread to the farm workers, and through their faeces flies will spread it over large distances.

“Colistin should only be used on very sick patients. Under any other circumstances it should be thought of and treated as an environmental toxin. It should be labelled as such. It should not be exported all over the world to be used in chicken feed.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.